AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease

AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease

Submission supported by data from the Phase 3 TEMPO program that demonstrated symptomatic improvement across the Parkinson's disease spectrumPositive results across all three Phase 3 TEMPO trials reinforce the potential of tavapadon, a novel selective dopamine D1/D5 receptor partial agonist,…

NDA Filed for Tavapadon as Once-Daily Oral Therapy for Parkinson Disease | NeurologyLive - Clinical Neurology News and Neurology Expert Insights

AbbVie’s application to the FDA for its selective dopamine D1/D5 receptor partial agonist is supported by data from the phase 3 TEMPO study program.

AbbVie Submits NDA for Parkinson’s Disease Drug, Tavapadon

Tavapadon is an investigational, novel, once-daily treatment option for Parkinson’s disease, which currently affects more than 1 million Americans.

AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease - Life Sciences British Columbia

NORTH CHICAGO, Ill - AbbVie announced a New Drug Application to the U.S. (FDA) for tavapadon, a treatment for Parkinson's disease.